Local health authorities in east China's Shandong province have suspended use of the vaccine, produced by Shenzen Kangtai Biological, Xinhua reported.
Shenzen Kangtai Biological is a privately run drug company with a 60 percent market share in China for hepatitis B vaccines.
The latest two fatalities occurred in Tancheng and Juancheng counties, the provincial center for disease control and prevention said.
The vaccination, which is a series of three shots, has been a successful step in the country's fight against viral hepatitis.
The World Health Organization has encouraged the use of the vaccination, Xinhua reported.